4-Bromoisoindolin-1-one: Applications of in Pharmaceutical Synthesis and its Preparation Method

General Description

4-Bromoisoindolin-1-one, a versatile compound with a bromine substitution at the 4-position and a ketone functionality at the 1-position, plays a crucial role in organic synthesis. It is a valuable intermediate in various fields, including pharmaceuticals. In pharmaceutical synthesis, it shows potential as an inhibitor targeting MetRS, crucial in protein synthesis and disease pathways. 4-Bromoisoindolin-1-one's structure allows for fine-tuning pharmacological properties, making it promising for drug development. Prepared through a two-step process, starting from methyl 3-bromo-2-(bromomethyl)benzoate, 4-Bromoisoindolin-1-one offers a pathway for creating novel therapeutics and advancing research in organic chemistry.

Figure 1. 4-Bromoisoindolin-1-one

Overview

4-Bromoisoindolin-1-one is a synthetic organic compound classified within the isoindoline family. Distinguished by its bromine substitution at the 4-position and a ketone functionality at the 1-position, 4-Bromoisoindolin-1-one possesses distinctive chemical attributes that render it a valuable intermediate in numerous organic synthesis pathways. The presence of the bromine group confers reactivity, facilitating subsequent derivatization, while the ketone moiety enables participation in various chemical transformations. Consequently, 4-Bromoisoindolin-1-one serves as a crucial component in medicinal chemistry and materials science, among other disciplines. Its capacity to undergo diverse reactions and yield stable intermediates endows it with significant utility as a foundational element in organic chemistry research and development endeavors. By virtue of its structural versatility and reactivity, 4-Bromoisoindolin-1-one is instrumental in the creation of novel compounds and materials, thereby advancing scientific exploration and innovation in multiple fields. ¹

Applications in Pharmaceutical Synthesis

4-Bromoisoindolin-1-one holds significant potential in pharmaceutical synthesis, particularly in the development of inhibitors targeting type 1 methionyl-tRNA synthetase (MetRS). This enzyme plays a crucial role in protein synthesis and is implicated in various diseases. The compound's structure, characterized by a bicyclic heteroaromatic core, aligns with the requirements for effective inhibition of MetRS. In the disclosed invention, it is synthesized through a multistep procedure, which likely involves bromination and cyclization reactions starting from suitable precursors. The resulting compound exhibits promising MetRS inhibitory activity. The application of 4-Bromoisoindolin-1-one and similar compounds in drug synthesis offers a targeted approach for treating diseases amenable to MetRS inhibition. By interfering with protein synthesis mediated by MetRS, these compounds hold potential in combating various diseases where dysregulated protein synthesis is implicated, including certain cancers and infectious diseases. Moreover, the structural versatility of the compound, allowing for substitution at various positions, enables medicinal chemists to fine-tune its pharmacological properties and optimize its efficacy and safety profile. Thus, 4-Bromoisoindolin-1-one emerges as a valuable scaffold in the development of novel therapeutics targeting MetRS, offering new avenues for drug discovery and treatment strategies in the pharmaceutical industry. ²

Preparation Method

4-Bromoisoindolin-1-one can be prepared through a two-step synthetic process. In the first step, methyl 3-bromo-2-(bromomethyl)benzoate is synthesized. This is achieved by reacting N-Bromosuccinimide with a suitable starting material  in the presence of benzoyl peroxide as a catalyst. The reaction takes place in benzene at reflux temperature for 5 hours. After the reaction is complete, the mixture is cooled, filtered, and the solid product is washed with diethyl ether. The filtrate is then treated with sodium thiosulfate and brine, dried, and concentrated. Purification of the residue is done through silica gel chromatography to obtain the desired product with a yield of 9.32g. In the second step, the obtained product from the first step is converted into 4-Bromoisoindolin-1-one. This transformation involves treating the product (Example 1B) with ammonium hydroxide in tetrahydrofuran at room temperature for 2 days. After completion of the reaction, the mixture is diluted with water, cooled, and filtered. The filter cake is washed and dried to obtain the desired product. The yield of 4-Bromoisoindolin-1-one is 3.34 g. Overall, these synthetic steps provide a route to obtain 4-Bromoisoindolin-1-one starting from simple precursors. ³

Reference

1. 4-Bromoisoindolin-1-one. National Center for Biotechnology Information. 2024; PubChem Compound Summary for CID 21907509.

2. Fan EK, Zhang ZS, Huang WL, Buckner FS. Preparation of bicyclic heteroaromatic compounds as inhibitors of type 1 methionyl-tRNA synthetase and methods of using them. 2018; Patent Number: WO2018237349.

3. Matulenko M, Jinkerson T, Brown BS. Isoindolinone derivatives as protein kinase inhibitors and their preparation and use for the treatment of pain. 2012; Patent Number: WO2012061602.

You may like